Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2016-11-09 Board/Management Inform…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Medicals valberedning inför årsstämman 2017 utsedd
Board/Management Information Classification · 99% confidence The document is a press release from Hansa Medical AB announcing the composition of the Nomination Committee (Valberedning) for the upcoming 2017 Annual General Meeting (Årsstämman). It details who the members are and outlines the committee's tasks, which are directly related to preparing proposals for the AGM (e.g., board members, remuneration). Although it mentions the AGM date and includes a financial calendar, the core subject is the formation and purpose of the body responsible for nominating candidates for the AGM. This falls under the scope of preparatory materials or information directly related to the AGM process, making 'AGM Information' (AGM-R) the most appropriate classification, as it is not the AGM presentation itself, but crucial related information.
2016-11-09 Swedish
Hansa Medical's Nomination Committee for the AGM 2017 appointed
Board/Management Information Classification · 99% confidence The document is a press release dated November 9, 2016, announcing the appointment of the Nomination Committee for the upcoming Annual General Meeting (AGM) in May 2017. It also publishes the financial calendar for 2017, which includes the date for the AGM. Since the primary focus is on the composition and function of the committee responsible for nominating directors and setting proposals for the AGM, this falls under the scope of AGM-related information, specifically concerning the preparatory steps for the meeting. It is not the AGM presentation itself, but preparatory material related to it. Therefore, AGM-R (AGM Information) is the most appropriate classification, as it deals directly with the governance and preparation for the Annual General Meeting.
2016-11-09 English
Kallelse till extra bolagsstämma i Hansa Medical AB (publ)
AGM Information Classification · 96% confidence The document is titled "Kallelse till extra bolagsstämma i Hansa Medical AB (publ)" which translates to 'Notice of Extraordinary General Meeting in Hansa Medical AB (publ)'. The text details the date, time, location, registration procedures, agenda items (including proposals for a directed new share issue and an incentive program), and voting rights for an upcoming shareholder meeting. This content is characteristic of a formal notice calling shareholders to a meeting, which aligns with the purpose of a Proxy Solicitation & Information Statement (PSI) or, more generally, materials related to a shareholder meeting. Since the document is a formal notice calling for an Extraordinary General Meeting (EGM) and outlines proposals to be voted upon, it strongly suggests it is related to soliciting shareholder votes and providing necessary information, fitting the definition of PSI (Proxy Solicitation & Information Statement). However, the core function described is the 'Notice' of the meeting itself, which often overlaps with AGM/EGM materials. Given the specific proposals (share issue, incentive plan) being put to a vote, PSI is the most precise fit among the options that cover shareholder meetings and associated materials, although 'AGM-R' (which covers AGM materials) is often used broadly for EGM materials too. Since it is a 'Kallelse' (Notice) detailing proposals for voting, PSI is the best fit for soliciting/informing for a vote, even if it's an EGM, not an AGM. If it were the results, it would be DVA. If it were just the presentation, it would be AGM-R. As the notice calling the meeting and detailing the proposals, PSI is appropriate.
2016-10-20 Swedish
Hansa Medical proposes a directed share issue
Capital/Financing Update Classification · 98% confidence The document is explicitly titled as a "PRESS RELEASE" and details a proposal by the board of directors for a "directed share issue of approximately SEK 185 million." This action involves raising capital through the issuance of new shares to selected investors, which directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition of Capital/Financing Update (CAP). Although it mentions an extraordinary general meeting, the primary focus is the financing transaction itself, not the voting results (DVA) or the notice for the meeting (which would be RPA/RNS if it were just an announcement of the notice). Since the core content is the proposed share issue and the associated fundraising, CAP is the most appropriate classification.
2016-10-20 English
Första patienten behandlad med IdeS i fas II-studie i förvärvad Trombotisk Trombocytopen Purpura (TTP)
Regulatory Filings Classification · 95% confidence The document is a press release dated October 11, 2016, announcing that the first patient has been treated in a Phase II clinical study for IdeS in acquired Thrombotic Thrombocytopenic Purpura (TTP). It details the study's purpose (safety, tolerability, efficacy), mentions the sponsor (Hansa Medical AB), and includes quotes from the CEO and the leading expert. Crucially, it contains the statement: "*Denna information är sådan information som Hansa Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning...*" (This information is such information that Hansa Medical AB is obliged to disclose according to the EU Market Abuse Regulation). This structure—a formal announcement of a material event (clinical trial initiation) mandated by market regulations—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement required by regulation but doesn't fit the specific definitions for earnings (ER), capital changes (CAP), or director dealings (DIRS), the most appropriate general regulatory category is Regulatory Filings (RNS). The document length (6232 chars) is substantial enough that it is the primary content, not just a link to a report, ruling out RPA.
2016-10-11 Swedish
First patient treated with IdeS in Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "PRESS RELEASE" dated October 11, 2016. It announces a specific corporate/clinical event: the treatment of the first patient in a Phase II study for a drug called IdeS in TTP. This type of announcement, detailing operational progress, clinical trial updates, and key highlights, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing clinical progress rather than a full financial report (10-K, IR) or a formal regulatory filing like a DEF 14A or DVA, the most appropriate classification among the provided options is Earnings Release (ER), as these often contain operational highlights, or Regulatory Filings (RNS) as a fallback. Given the content focuses on clinical trial progress and is structured as a press release, it aligns best with the function of an ER (announcing key period/operational results) or RNS (general regulatory disclosure). Since it is not a formal earnings report but a specific operational update, RNS is a strong candidate, but ER often encompasses press releases announcing significant operational milestones. However, looking closely at the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical trial update, not a financial results highlight. Therefore, the best fit is the general regulatory announcement category, RNS, as it covers miscellaneous filings that don't fit elsewhere, especially press releases about clinical progress.
2016-10-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.